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Sialic acid-binding lectin (SBL) is a multi-functional protein that is isolated from oocytes of
Rana catesbeiana. It has both lectin and ribonuclease (enzyme) properties, and therefore
is called leczyme. We examined the anti-tumor effects of SBL and discovered that SBL
has potential as a new type of anti-cancer drug. SBL causes a cancer-selective induction
of apoptosis by multiple signaling pathways whereby RNA is its target. It is suggested
that the mitochondrial pathway and endoplasmic reticulum stress-mediated pathway par-
ticipate in SBL-induced signaling. The synergistic anti-tumor effects with other molecules,
such as tumor necrosis factor-related apoptosis ligand and interferon γ, have been reported.
In this study, we summarize the effects of SBL and focus on its cancer-selective apoptotic
properties. In addition, we present a possible explanation for its cancer specificity.
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INTRODUCTION
Sialic acid-binding lectin (SBL), also named RC-ribonuclease
(RNase), is isolated from oocytes of Rana catesbeiana. It is a basic
protein consisting of 111 amino acids and 4 disulfide bonds (1–4).
Functional studies of SBL reveal that SBL is a multi-functional
protein having both lectin and RNase activities, and therefore it is
now called “leczyme” (5–8). Furthermore, from studies investigat-
ing medicinal ribonucleases from frog oocytes, it has been revealed
that SBL has remarkable anti-tumor effects that selectively target
cancer cells (9).
Sialic acid-binding lectin was found to be an agglutinin of can-
cer cells because it agglutinates a large variety of cancer cells (1).
Because SBL-induced agglutination is strongly inhibited by glyco-
proteins such as mucin but not asialomucin, and sialidase-treated
cells reduce the cell agglutination induced by SBL, it is believed
that the binding of SBL to glycoconjugates containing sialic acid
on the cell surface contributes to the cell agglutination activity
of SBL (2, 9). Selectivity for cancer cells is an important prop-
erty of SBL. SBL reacts with many kinds of cancer cells, such as
lung, gastric, cervical carcinoma, and leukemias, but not normal
cells, such as fibroblast, lymphocytes, and erythrocytes (2). This
cancer-selective agglutination activity of SBL may contribute to its
cancer-selective apoptosis-inducing effects that we will discuss.
From the results of amino acid sequence analyses, it was found
that SBL exhibits homology to various members of the RNase
A superfamily (3, 6). SBL has conserved catalytic amino acids
residues for RNase activity (one lysine and two histidines) and
has pyrimidine base-specific RNase activity, which is a typical fea-
ture of the RNase A superfamily. The RNase activity of SBL is not
inhibited by the human ribonuclease inhibitor (RI) (9), and this
explains why SBL exerts an anti-tumor effect even though other
mammalian members of the RNase A superfamily, which is tightly
captured by human RI, do not show anti-tumor effects.
An anti-tumor effect of SBL was reported in both in vitro (P388
and L1210 cell lines) and in vivo (mouse ascites Sarcoma 180, Mep
II, and Ehrlich cells) experiments (9). It has been considered that
the SBL-induced anti-tumor effect is attributed to the coopera-
tion of two actions; lectin activity that recognizes glycoconjugates
containing sialic acid on the cell surface and RNase activity that
cleaves cellular RNA. SBL shows cytotoxic effects in a large variety
of cancer cells including P-glycoprotein overexpressed multi-drug
resistant (MDR) cells (10, 11). Replicative DNA is the main tar-
get of traditional anti-cancer agents. The development of these
reagents makes a great contribution to the progression of cancer
therapy; however, side effects stemming from their low selectiv-
ity and resistance to these reagents are still significant problems.
Because SBL exerts cancer-selective anti-tumor effects regardless
of P-glycoprotein expression via new mechanisms that target RNA,
it is expected that SBL has a potential as an alternative to con-
ventional DNA-damaging anti-cancer drugs. In this study, we
summarize the effects of SBL, and particularly focus on the cancer-
selective induction of apoptosis. In addition, we propose a possible
explanation for the cancer specificity of SBL.
SBL-INDUCED APOPTOSIS
Sialic acid-binding lectin inhibits the growth of several cancer
cell lines in vivo by abrogating solid tumor growth and ascites
accumulation in mice at a non-toxic dose; therefore, prolonging
the life span of tumor-bearing mice (9). It has been suggested
that SBL binds to the target cell surface, internalizes into the cell
by endocytosis, decomposes RNA in the cytosol, and then leads
to the induction of an apoptotic signal. We recently investigated
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the potential mechanism of this SBL-induced cytotoxicity using
human leukemia cell lines and malignant mesothelioma cell lines
(10, 12). We found that SBL induces apoptosis in a caspase
activation-dependent manner. SBL causes rigid mitochondrial
perturbation before caspase activation; therefore, implicating an
intrinsic apoptotic signaling pathway. Moreover, we reported the
possible participation of endoplasmic reticulum stress in SBL-
induced apoptosis (13). It was apparent that SBL causes mitochon-
dria perturbation and endoplasmic reticulum stress independently
and the mitochondrial pathway may be intensely involved in
apoptosis induced by SBL.
In terms of other factors that affect SBL-induced apoptosis, we
have reported that the heat shock protein (Hsp) 70 plays a role
in the SBL-induced anti-tumor effect (11, 14). The reduction of
Hsp70 expression results in an attenuated induction of apoptosis.
Because the binding of SBL to P388 cell membrane is not affected
by the decreased expression of Hsp70, we speculate that Hsp70
may interact with the SBL receptor or participate in the pene-
tration of SBL into cells and subsequently affect the cytotoxicity
of SBL.
SENSITIVITY OF CELLS AGAINST SBL
The anti-tumor effect of SBL has been examined in several
different cancer cell lines and primary or immortalized non-
malignant cells (Table 1). To date, 33 tumor and 8 normal cell
lines have been determined to be sensitive or insensitive. In gen-
eral, SBL suppresses the growth of various kinds of cancer cells
[carcinoma (cervical, hepatocellular, oral, and breast), sarcoma,
mesothelioma, leukemia (T-cell, promyelotic, and erythro), and
lymphoma] but not normal cells (fibroblast, melanocytes, ker-
atinocytes, and mesothelial cells). The sensitivities of some cancer
cell lines (MCF-7, and Raji) are contradictory between reports
but such contradictions may be caused by different experimental
conditions and/or that MCF-7 and Raji have moderate level of
sensitivity to SBL.
The first report that discovered an anti-proliferative effect of
SBL was performed on mouse leukemia P388 and L1210 cell
lines (9). Further investigation revealed that sialidase treatment
of the cells reduces the sensitivity for SBL. Subsequently, the SBL-
resistant P388 cell variant RC-150 cell line was established (15).
Because SBL binds to both P388 and RC-150 cells but only enters
P388 cells, it is suggested that RC-150 cells have a defective inter-
nalization mechanism. These results indicate that SBL needs to
bind to the cancer cell surface and internalize into cytosol for
execution of its anti-tumor activity.
A few years later, Liao et al. reported that SBL inhibits the
growth of several carcinoma cell lines but does not affect normal
human and mouse fibroblasts (16). Hu et al. reported a phe-
nomenon using human hepatoma cell lines that has a distinct
differentiation extent (17). The distinct cytotoxicity of SBL in dif-
ferent hepatoma cells correlates with the differentiation extent
but not the proliferation rate of the cells. Wei et al. reported
a similar phenomenon that retinoic acid (RA) or dimethylsul-
foxide (DMSO)-induced differentiation resulted in HL-60 cells
becoming resistant to SBL (18). These results indicate that dif-
ferentiation is a significant factor for the selective cytotoxicity
of SBL.
Onconase (ONC) is a promising RNase for medicinal appli-
cations. ONC was isolated from oocytes of R. pipience and
shows approximately 50% homology with SBL in the amino acid
sequence (19–21). Only a few investigations have compared the
effects of ONC and SBL. Tang et al. report that compared with
ONC, SBL harbors a more specific anti-cancer activity because
ONC is toxic to normal human HS-68 foreskin fibroblasts but
SBL is not toxic in their study (22).
Tseng et al. discovered another factor that is selective in the
treatment of breast carcinoma cell lines with SBL. They tested
several breast cancer cell lines and revealed that SBL induces cell
death on estrogen receptor (ER)-positive breast tumors but not on
ER-negative breast tumors. The anti-tumor effect of SBL-treated
ER-positive breast tumors is accompanied by the down-regulation
of ER and Bcl-2. They also showed that Bcl-2 overexpression,
but not Bcl-XL overexpression, significantly inhibits the effect
(23). Furthermore, Lee et al. showed that SBL does not affect
the cell survival of normal hamster fibroblast BHK-21 cells but
SBL does induce apoptosis in Japanese encephalitis virus (JEV)-
infected BHK-21 cells. They showed that JEV infection enhances
the internalization of SBL into cells (24).
To summarize, most cancer cells are sensitive to SBL, but all
normal cells tested so far are insensitive to SBL. In addition, the
sensitivity does not correlate with the proliferation rate of the
cells. The binding of SBL to the cell surface, internalization of SBL
into the cell, expression of some kinds of molecules such as ER,
Bcl-2 Hsp70, and JEV infection, are all factors that affect the cell
sensitivity to SBL.
CANCER SPECIFICITY (PREDICTED POSSIBILITY) AND
FACTORS THAT INFLUENCE THE EFFECTS OF SBL
Only a paucity of information is available on how SBL specifically
induces apoptosis in cancer cells. Based on the aforementioned
studies, some potential mechanisms can be suggested. The pro-
posed mechanism for SBL-induced apoptosis and the factors that
influence the effects of SBL are summarized in Figure 1. SBL
induces cancer-selective apoptosis via the following stages: (i) SBL
binds to the cancer cell surface, (ii) SBL internalizes and translo-
cates to the cytosol, (iii) it degrades cellular RNA, and (iv) then
SBL-induced ribotoxic stress transduces an apoptotic signal via
the mitochondria and endoplasmic reticulum. Factors that affect
the above stages would influence the SBL-induced apoptosis. As
we mentioned earlier, the binding of SBL is diminished by coex-
isting highly sialylated proteins such as mucin or treatment of the
cells with sialidase (9). It is known that changes of glycosylation
patterns on the plasma membrane occur during tumorigenesis
(25, 26) and that many kinds of cancer result in an increase in the
anionic content such as sialic acids on the membrane (27). There-
fore, there is a possibility that an increase of anionic molecules on
the cell surface may facilitate the adsorption of SBL. However, the
agglutination activity of SBL is not affected by sialic acid itself (9).
In addition, SBL does not agglutinate normal red blood cells even
if there are sialylated molecules on the cells (2). These observations
indicate that the particular structure recognized by SBL may reside
in the target molecules on cancer cell membrane. Therefore, the
existence of a receptor molecule for SBL has been suggested. It is
possible that quantitative and qualitative changes of the receptor,
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Table 1 | Cells that are reported to be sensitive or insensitive to SBL.
Reference Cells Characteristics Anti-tumor
effect of SBL
Comments
Nitta et al.
(9)
P388 Mouse leukemia + Anti-proliferative effect of SBL is
diminished by sialidase treatment of cellsP388 Mouse leukemia Sialidase-treated −
L1210 Mouse leukemia +
Sarcoma 180 Mouse ascites (in vivo experiments) + SBL inhibits the tumor growth in mice
Mep II Mouse ascites (in vivo experiments) +
Ehrlich Mouse ascites (in vivo experiments) +
Nitta et al.
(15)
P388 Mouse leukemia cells + SBL binds to RC-150 but not internalized
into the cellsRC-150 SBL-resistant P388 cell variant −
Liao et al.
(16)
HFW Normal human fibroblast − SBL inhibits cell growth specific to cancer
cellsNIH3T3 Normal mouse embryonic fibroblast −
CaSki Human cervical carcinoma +
HA-22T Human hepatocellular carcinoma +
KB Human oral carcinoma +
SK-Hep-1 Human hepatocellular carcinoma +
Hela Human cervical carcinoma +
Differentiation The distinct cytotoxicity of SBL on
different hepatoma cells was correlated
with the differentiation extent but not the
proliferation rate of the cells
Hu et al.
(17)
SK-Hep-1 Human hepatocellular carcinoma Poorly +++
J5 Human hepatocellular carcinoma Intermediately ++
Hep G2 Human hepatocellular carcinoma Well +
BHK-21 Normal hamster fibroblast − −
Hu et al.
(34)
MCF-7 Human breast carcinoma ++ Overexpression of Bcl-XL diminishes
cytotoxicity of SBLMCF-7/Bcl-XL Bcl-XL overexpressed MCF-7 +
Differentiation Differentiation is a significant factor of the
selective cytotoxicity of SBLWei et al.
(18)
HL-60 Human promyelocytic leukemia − +
HL-60 (RA) RA treat HL-60 Induced −
HL-60 (DMSO) DMSO treated HL-60 Induced −
Tang et al.
(22)
HL-60 Human promyelocytic leukemia + SBL inhibits cell growth specific to cancer
cells. SBL seems to harbor a more
specific anti-cancer activity, compared
with Onconase
MCF-7 Human breast carcinoma +
SK-Hep-1 Human hepatocellular carcinoma +
HS-68 Normal human HS-68 foreskin
fibroblast
−
ER SBL induces cell death on ER-positive
breast tumors but not on ER-negative
breast tumors through down-regulation of
ER and Bcl-2. The anti-cancer effect on
SBL-treated ER-positive breast tumors is
related to Bcl-2 overexpression, but not to
Bcl-XL overexpression
Tseng et al.
(23)
MCF-7 Human breast carcinoma cells + +
MDA-MB-231 Human breast carcinoma cells − −
ZR-75-1 Human breast carcinoma cells + +
ZR-75-30 Human breast carcinoma cells − −
MCF-7/Bcl-2 Bcl-2 overexpressed MCF-7 + −
MCF-7/Bcl-XL Bcl-XL overexpressed MCF-7 + +
Lee et al.
(24)
BHK-21 Normal hamster fibroblast − SBL induces apoptosis to JEV-infected
BHK-21 cellsBHK-21 (JEV) JEV-infected BHK-21 cells +
Tatsuta
et al. (10)
Jurkat Human T-cell leukemia ++ SBL shows anti-proliferative effect of
various leukemia cells including MDR cellsK562 Human erythroleukemia +
K562/adr Human
P-glycoprotein-overexpressing K562
cells
+
U937 Human promyelocytic leukemia +
Raji Human Burkitt’s lymphoma +
(Continued)
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Table 1 | Continued
Reference Cells Characteristics Anti-tumor
effect of SBL
Comments
Ogawa
et al. (11)
P388 Mouse leukemia +++ Differing sensitivities are predicted to
arise from the differences in cell surface
components
K562 Human erythroleukemia ++
HL-60 Human promyelocytic leukemia +
MCF-7 Human breast carcinoma cells −
Daudi Human Burkitt’s lymphoma −
Raji Human Burkitt’s lymphoma −
NHDF Normal human epidermal fibroblasts −
NHEM Normal human epidermal
melanocytes
−
NHEK Normal human keratinocytes −
Tatsuta
et al. (12)
H28 Human malignant mesothelioma ++ SBL induces cancer-selective apoptosis
against malignant mesotheliomaMeso-1 Human malignant mesothelioma +
Meso-4 Human malignant mesothelioma +
Met-5A Normal human mesothelial cells −
Cells including 33 tumor cell lines and 8 primary or immortalized non-malignant cells were reported the sensitiveness for SBL. Relative intensity of anti-tumor effects
was assessed with respect to each paper, and indicated as +, ++, +++, or −. RA, retinoic acid; DMSO, dimethylsulfoxide; ER, estrogen receptor; JEV, Japanese
encephalitis virus. Normal cells and negative effect were emphasized with blue and pink background, respectively.
such as specific or increased expression of the receptor and con-
formational or environmental divergence of the receptor, could
affect the receptor affinity of SBL and contribute to the selectivity
of SBL.
It is apparent in SBL-resistant RC-150 cells that SBL is required
to internalize into the cells to show its anti-tumor effect (15).
Therefore, there are factors that regulate the cell sensitivity to
SBL by influencing the internalization or translocation of SBL
and binding of SBL is not likely to be affected by such fac-
tors. The cytotoxic ribonuclease bovine seminal (BS)-RNase has
been reported to bind both normal and malignant cells but it
only demonstrates a cytotoxic effect in malignant cells. It is
suggested that the differences in intracellular route for inter-
nalization contribute to the selectivity of BS-RNase (28–30). In
this respect, there are several possible factors that may pro-
duce the cancer selectivity of SBL by affecting the internaliza-
tion or translocation of SBL. The members of the Hsp fam-
ily form a complex and interact with some receptors such as
epidermal growth factor receptor (31, 32) or rota virus recep-
tor (integrin αvβ3) (33) and regulate receptor including ligand
binding and penetration. However, reducing Hsp70 expression
does not affect the binding of SBL but instead attenuates its
apoptosis-inducing effects. This indicates that Hsp70 participates
in the intracellular routing of SBL. A JEV infection, mentioned
earlier as a promoting factor, enhances the internalization of
SBL (24).
Tseng et al. reported that the overexpression of Bcl-2 in a
MCF-7 cell line diminishes SBL-induced apoptosis (23). We have
shown that SBL causes a rigid mitochondrial perturbation during
the early stages of apoptosis initiation (10). Because the anti-
apoptotic Bcl-2 family regulates apoptosis by retaining mitochon-
drial normality, it can be considered that Bcl-2 overexpression
reduces SBL-induced apoptosis by affecting the mitochondria
perturbation-inducing effect of SBL.
The synergistic effects of SBL with other molecules have been
reported. We recently reported that SBL exerts synergistic anti-
tumor effects with tumor necrosis factor-related apoptosis ligand
(TRAIL) against a malignant mesothelioma cell line (12). The syn-
ergistic effects were caused by the amplification of an apoptotic
signal in which Bid truncation and caspase activation resulted in
drastic mitochondria perturbations (12). The combination treat-
ment of SBL with interferon γ (IFN-γ) enhances apoptosis in
MCF-7 and SK-Hep-1 cells (22, 34). Hu et al. proposed that IFN-γ
somehow upregulates the expression of the SBL receptor on the cell
membrane, facilitates the entry of SBL, and then results in severe
cell death (34). Tang et al. found that the synergistic cytotoxicity
with IFN-γ is not observed in HL-60 cells. Since SBL-induced cell
death is differentiation dependent and IFN-γ is known to induce
the differentiation of HL-60 cells, they suggested that this may
occur because the differentiation status of HL-60 cells is altered
by IFN-γ and such a change in the differentiation status protects
some cell types from synergistic cytotoxicity (22).
Even if the differentiation extent and expression of ER are
shown to be significant factors for cell sensitivity to SBL, the
mechanisms remain to be elucidated. Low differentiated or ER-
positive cells may express abundant SBL receptors or have an
internalization-facilitative system for SBL. However, factors that
affect SBL binding, internalization, RNA degradation, and apop-
totic signal transduction are most likely the important contribu-
tors to SBL cell sensitivity. Furthermore, we assume that there are
differences in the factors involved in cancer and normal cells. A
comparative study that examines the SBL binding and internal-
ization in different cancer, normal, and these-factor affected cells
may help reveal the key mechanisms involved.
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FIGURE 1 | Predicted mechanism of sialic acid-binding lectin
(SBL)-induced apoptosis and proposed factors that influence the effects
of SBL. SBL binds to the cancer cell surface and then internalizes into cell. It
subsequently degrades RNA in the cytosol leading to the induction of an
apoptotic signal. The existence of a SBL receptor, a sialylated glycoconjugate,
has been speculated. SBL induces apoptosis in a caspase
activation-dependent manner. SBL causes mitochondria perturbations and
also endoplasmic reticulum stress independently. The mitochondrial pathway
is intensely involved in apoptosis induced by SBL. The proposed factors that
influence the effects of SBL are indicated on the right and their sites of action
are shown. The extent of differentiation and expression of ER are also factors,
but their sites of action remain to be elucidated.
CONCLUSION
Sialic acid-binding lectin is a leczyme that has both lectin and
RNase activity. SBL elicits anti-tumor effects by degrading cellular
RNA and subsequently inducing apoptosis via a mitochondria
and endoplasmic reticulum stress-mediated pathway. SBL could
be an innovative anti-cancer reagent because SBL induces apopto-
sis in cancer cells regardless of the P-glycoprotein expression and it
exerts synergistic apoptosis-inducing effects with other molecules
such as TRAIL and IFN-γ. SBL exhibits a high selectivity for cancer
cells. Future comprehensive analyses of the SBL binding mecha-
nisms and internalization of SBL into different cell lines will assist
in determining the selectivity of SBL and help to discover new
targets for cancer therapy.
ACKNOWLEDGMENTS
This study was supported in part by Grant-in-Aid of the “Acad-
emic Frontier” Project (2006–2011) and the “Strategic Research”
Project (2012–2017) for Private Universities from the Ministry of
Education, Culture, Sports, Science and Technology of Japan.
REFERENCES
1. Kawauchi H, Sakakibara F, Watanabe K. Agglutinins of frog eggs: a new class
of proteins causing preferential agglutination of tumor cells. Experientia (1975)
31:364–5. doi:10.1007/BF01922588
2. Nitta K, Takayanagi G, Kawauchi H, Hakomori S. Isolation and characteriza-
tion of Rana catesbeiana lectin and demonstration of the lectin-binding gly-
coprotein of rodent and human tumor cell membranes. Cancer Res (1987) 47:
4877–83.
www.frontiersin.org June 2014 | Volume 4 | Article 139 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tatsuta et al. Apoptotic cancer cell death by leczyme
3. Titani K, Takio K, Kuwada M, Nitta K, Sakakibara F, Kawauchi H, et al. Amino
acid sequence of sialic acid binding lectin from frog (Rana catesbeiana) eggs.
Biochemistry (1987) 26:2189–94. doi:10.1021/bi00382a018
4. Liao YD. A pyrimidine-guanine sequence-specific ribonuclease fromRana cates-
beiana (bullfrog) oocytes. Nucleic Acids Res (1992) 20:1371–7. doi:10.1093/nar/
20.6.1371
5. Okabe Y, Katayama N, Iwama M, Watanabe H, Ohgi K, Irie M, et al. Compara-
tive base specificity, stability, and lectin activity of two lectins from eggs of Rana
catesbeiana andR. japonica and liver ribonuclease fromR. catesbeiana. J Biochem
(1991) 109:786–90.
6. Nitta K, Oyama F, Oyama R, Sekiguchi K, Kawauchi H, Takayanagi Y, et al.
Ribonuclease activity of sialic acid-binding lectin from Rana catesbeiana eggs.
Glycobiology (1993) 3:37–45. doi:10.1093/glycob/3.1.37
7. Nitta K, Ozaki K, Tsukamoto Y, Hosono M, Ogawakonno Y, Kawauchi H, et al.
Catalytic lectin (leczyme) from bullfrog (Rana catesbeiana) eggs. Int J Oncol
(1996) 9:19–23.
8. Nitta K. Leczyme. Methods Enzymol (2001) 341:368–74. doi:10.1016/S0076-
6879(01)41164-5
9. Nitta K, Ozaki K, Ishikawa M, Furusawa S, Hosono M, Kawauchi H, et al. Inhibi-
tion of cell proliferation byRana catesbeiana andRana japonica lectins belonging
to the ribonuclease superfamily. Cancer Res (1994) 54:920–7.
10. Tatsuta T, Hosono M, Sugawara S, Kariya Y, Ogawa Y, Hakomori S, et al. Sialic
acid-binding lectin (leczyme) induces caspase-dependent apoptosis-mediated
mitochondrial perturbation in Jurkat cells. Int J Oncol (2013) 43:1402–12.
doi:10.3892/ijo.2013.2092
11. Ogawa Y, Sugawara S, Tatsuta T, Hosono M, Nitta K, Fujii Y, et al. Sialyl-
glycoconjugates in cholesterol-rich microdomains of P388 cells are the trig-
gers for apoptosis induced by Rana catesbeiana oocyte ribonuclease. Glycoconj J
(2014) 31:171–84. doi:10.1007/s10719-013-9513-7
12. Tatsuta T, Hosono M, Takahashi K, Omoto T, Kariya Y, Sugawara S, et al. Sialic
acid-binding lectin (leczyme) induces apoptosis to malignant mesothelioma and
exerts synergistic antitumor effects with TRAIL. Int J Oncol (2014) 44:377–84.
doi:10.3892/ijo.2013.2192
13. Tatsuta T, Hosono M, Miura Y, Sugawara S, Kariya Y, Hakomori S, et al.
Involvement of ER stress in apoptosis induced by sialic acid-binding lectin
(leczyme) from bullfrog eggs. Int J Oncol (2013) 43:1799–808. doi:10.3892/ijo.
2013.2128
14. Tatsuta T, Hosono M, Ogawa Y, Inage K, Sugawara S, Nitta K. Downregulation of
Hsp70 inhibits apoptosis induced by sialic acid-binding lectin (leczyme). Oncol
Rep (2014) 31:13–8. doi:10.3892/or.2013.2814
15. Nitta K, Ozaki K, Tsukamoto Y, Furusawa S, Ohkubo Y, Takimoto H, et al. Char-
acterization of aRana catesbeiana lectin-resistant mutant of leukemia P388 cells.
Cancer Res (1994) 54:928–34.
16. Liao YD, Huang HC, Chan HJ, Kuo SJ. Large-scale preparation of a ribonucle-
ase from Rana catesbeiana (bullfrog) oocytes and characterization of its spe-
cific cytotoxic activity against tumor cells. Protein Expr Purif (1996) 7:194–202.
doi:10.1006/prep.1996.0027
17. Hu CC, Lee YH, Tang CH, Cheng JT, Wang JJ. Synergistic cytotoxicity of Rana
catesbeiana ribonuclease and IFN-gamma on hepatoma cells. Biochem Biophys
Res Commun (2001) 280:1229–36. doi:10.1006/bbrc.2001.4272
18. Wei CW, Hu CC, Tang CH, Lee MC,Wang JJ. Induction of differentiation rescues
HL-60 cells from Rana catesbeiana ribonuclease-induced cell death. FEBS Lett
(2002) 531:421–6. doi:10.1016/S0014-5793(02)03577-9
19. Darzynkiewicz Z, Carter SP, Mikulski SM, Ardelt WJ, Shogen K. Cytostatic and
cytotoxic effects of Pannon (P-30 protein), a novel anticancer agent. Cell Tissue
Kinet (1988) 21:169–82.
20. Mosimann SC, Johns KL,Ardelt W, Mikulski SM, Shogen K, James MN. Compar-
ative molecular modeling and crystallization of P-30 protein: a novel antitumor
protein of Rana pipiens oocytes and early embryos. Proteins (1992) 14:392–400.
doi:10.1002/prot.340140308
21. Irie M, Nitta K, Nonaka T. Biochemistry of frog ribonucleases. Cell Mol Life Sci
(1998) 54:775–84. doi:10.1007/s000180050206
22. Tang CH, Hu CC, Wei CW, Wang JJ. Synergism of Rana catesbeiana ribonuclease
and IFN-gamma triggers distinct death machineries in different human cancer
cells. FEBS Lett (2005) 579:265–70. doi:10.1016/j.febslet.2004.11.086
23. Tseng HH,YuYL, ChenYL, Chen JH, Chou CL, Kuo TY, et al. RC-RNase-induced
cell death in estrogen receptor positive breast tumors through down-regulation
of Bcl-2 and estrogen receptor. Oncol Rep (2011) 25:849–53. doi:10.3892/or.
2010.1114
24. Lee YH, Wei CW, Wang JJ, Chiou CT. Rana catesbeiana ribonuclease inhibits
Japanese encephalitis virus (JEV) replication and enhances apoptosis of JEV-
infected BHK-21 cells. Antiviral Res (2011) 89:193–8. doi:10.1016/j.antiviral.
2011.01.002
25. Dennis JW, Granovsky M, Warren CE. Glycoprotein glycosylation and can-
cer progression. Biochim Biophys Acta (1999) 1473:21–34. doi:10.1016/S0304-
4165(99)00167-1
26. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bot-
tle. Proc Natl Acad Sci U S A (2002) 99:10231–3. doi:10.1073/pnas.172380699
27. Wang FL, Cui SX, Sun LP, Qu XJ, Xie YY, Zhou L, et al. High expres-
sion of alpha 2, 3-linked sialic acid residues is associated with the metasta-
tic potential of human gastric cancer. Cancer Detect Prev (2009) 32:437–43.
doi:10.1016/j.cdp.2009.01.001
28. Bracale A, Spalletti-Cernia D, Mastronicola M, Castaldi F, Mannucci R, Nitsch L,
et al. Essential stations in the intracellular pathway of cytotoxic bovine seminal
ribonuclease. Biochem J (2002) 362:553–60. doi:10.1042/0264-6021:3620553
29. Mastronicola MR, Piccoli R, D’Alessio G. Key extracellular and intracellular
steps in the antitumor action of seminal ribonuclease. Eur J Biochem (1995)
230:242–9. doi:10.1111/j.1432-1033.1995.tb20557.x
30. Vescia S, Tramontano D, Augusti-Tocco G, D’Alessio G. In vitro studies on selec-
tive inhibition of tumor cell growth by seminal ribonuclease. Cancer Res (1980)
40:3740–4.
31. Dong J, Guo L, Liao Z, Zhang M, Zhang M, Wang T, et al. Increased expres-
sion of heat shock protein 70 in chronic obstructive pulmonary disease. Int
Immunopharmacol (2013) 17:885–93. doi:10.1016/j.intimp.2013.09.003
32. Pillai RN, Ramalingam SS. Heat shock protein 90 inhibitors in non-small-
cell lung cancer. Curr Opin Oncol (2014) 26:159–64. doi:10.1097/CCO.
0000000000000047
33. Guerrero CA, Moreno LP. Rotavirus receptor proteins Hsc70 and integrin
alphavbeta3 are located in the lipid microdomains of animal intestinal cells.
Acta Virol (2012) 56:63–70. doi:10.4149/av_2012_01_63
34. Hu CC, Tang CH, Wang JJ. Caspase activation in response to cytotoxic
Rana catesbeiana ribonuclease in MCF-7 cells. FEBS Lett (2001) 503:65–8.
doi:10.1016/S0014-5793(01)02691-6
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 28 March 2014; accepted: 21 May 2014; published online: 04 June 2014.
Citation: Tatsuta T, Sugawara S, Takahashi K, Ogawa Y, Hosono M and Nitta K
(2014) Cancer-selective induction of apoptosis by leczyme. Front. Oncol. 4:139. doi:
10.3389/fonc.2014.00139
This article was submitted to Molecular and Cellular Oncology, a section of the journal
Frontiers in Oncology.
Copyright © 2014 Tatsuta, Sugawara, Takahashi, Ogawa, Hosono and Nitta. This is
an open-access article distributed under the terms of the Creative CommonsAttribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original publica-
tion in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Oncology | Molecular and Cellular Oncology June 2014 | Volume 4 | Article 139 | 6
